1

under the auspices of the Federal Minister Hermann Gröhe

10 – 11 March 2016

Main Lecture Hall (Aula)Friedrich Schiller University JenaFürstengraben 1 · 07743 Jena

SepsisThe challenges of science, politics and society

Joint symposium by the Jena University Hospital andthe German Nati onal Academy of Sciences Leopoldina

Foto

: © K

linis

ches

Med

ienz

entr

um

2

German National Academy of Sciences Leopoldina

Founded in 1652, the Leopoldina brings together some 1,500 outstanding scientists from about 30 countries. It is dedicated to the advancement of science for the benefit of humankind and to shaping a better future. In its role as the German National Aca-demy of Sciences, the Leopoldina represents the German scien-tific community in international committees. It offers unbiased scientific opinions on political and societal questions, publishing independent studies of national and international significance. The Leopoldina promotes scientific and public debate, supports young scientists, confers awards for scientific achievements, conducts research projects, and campaigns for the human rights of persecuted scientists.

3

Introduction

Sepsis continues to cause millions of deaths worldwide of which at least two million fatalities could be avoided each year by pre-ventive measures such as vaccination of risk populations, better sanitation and clean care, as well as by early recognition and most basic elements of care. In addition, at least 2 million sepsis sur-vivors per year suffer from significant long term complications of the syndrome. Currently, adequate treatment facilities for most of these patients are missing. Despite its high and increasing inciden-ce sepsis is poorly recognized by health authorities, health care workers, policymakers, lay people and media. The implementation of effective measures for sepsis control and the development of improved infection and sepsis diagnostics, effective antimicrobials and sepsis specific therapies are urgently needed.

4

We are pleased that this Leopoldina Symposium* brings together highly ranked policy makers, representatives of national and inter-national health care authorities, most renowned clinical scientists, basic researchers, representatives of highly innovative diagnostic and pharmaceutic companies, media and communication experts and sepsis survivors to learn from each other about the most ef-fective ways to:

· Increase vaccination rates and adherence to hygienic standards

· Improve preparedness in case of further pandemics

· Increase awareness for sepsis among lay people and health care providers

· Foster quality improvement projects in the hospital and outpatient setting

· Implement antibiotic stewardship programs and stop the misuse of antimicrobials

· Overcome the gap between resistance, novel and effective antimicrobials

· Encourage the development of cost-effective diagnostics and sepsis-specific therapeutics

· Develop and provide adequate treatment concepts for sepsis sequelae

We are convinced that the outcomes of this symposium will in-crease the understanding of the need for national and internati-onal efforts, action plans and resolutions to fight life-threatening infections and sepsis. For this reason, we cordially invite you to join us for this meeting in the main auditorium of Friedrich Schiller University Jena.

Michael Bauer Axel Brakhage Konrad ReinhartCenter for Sepsis Control and Care InfectControl2020 Sepsis-Stiftung

* Die Fortbildung wurde durch die LÄK Thüringen anerkannt und wird mit 17 Punkten der Kategorie A bewertet.

5

Foreword

Sepsis is a potentially life-threatening complica-tion of an infection. It is one of the most unde-restimated health risks. Every year, more than 279,000 patients develop sepsis in Germany and over 67,000 die of this condition. As a result, sepsis is the third most frequent cause of death in Germany. The Global Sepsis Alliance puts the

number of affected per year at 30 million persons, more than one-fifth of whom die as a result. However, even those patients who survive often suffer for the rest of their lives from the physical and mental sequelae. This development gives us reason for concern.

In recent years, the number of sepsis cases has been on the in-crease. There are several reasons for this. Owing to the prevailing demographic trends, we now have more elderly patients who eit-her have chronic diseases or need to undergo invasive treatment and operations. Treatment procedures that lead to a weakening of the immune system, such as chemotherapies, are becoming increasingly frequent. Another reason for the rise in sepsis cases is the increase in antibiotic resistance and the resulting failure of hitherto successful treatments.

Appropriate measures could contribute to reducing the number of sepsis cases. These measures include the vaccination of risk groups

Bund

esre

gier

ung/

Steff

en K

ugle

r

6

against infectious diseases, stricter adherence to hygiene measu-res, early detection and treatment of sepsis, as well as a reduction in antibiotic resistance by promoting the proper use of antibiotics. Furthermore, it is necessary to educate both medical personnel and citizens about this condition. Indeed, a major risk lies in the lack of knowledge that prevails with respect to this disease. This is why I am very pleased that the Leopoldina has chosen to organise this ‚Sepsis Symposium‘. It is providing experts from all over the world with an opportunity for exchange, both on the challenges posed to science and policy and on the various strategies deployed in fighting sepsis.

In a move to control antibiotic resistance and reduce healthcare-as-sociated infections, the Federal Government has moved, in recent years, to tighten laws, expand the existing tools and develop new measures and opportunities. In collaboration with the Federal Mi-nistry of Food and Agriculture and the Federal Ministry of Educati-on and Research, the German Antibiotic Resistance Strategy ‚DART 2020‘ was drawn up and adopted by the Federal Cabinet in May 2015. Multi-disciplinary co-operation in combating antibiotic re-sistance in human and veterinary medicine is at the forefront of the DART 2020 activities. A further key goal is better education of the population with respect to antibiotic resistance and the pro-vision of comprehensive information on the quality of hygiene in hospitals. Furthermore, we intend to further develop the monito-ring systems for antibiotic resistance and antibiotic use. This will enable us to detect new pathogens and forms of resistance at an early stage and thereby gain important data for the development and adaptation of treatment and hygiene recommendations.

Together with other German-speaking health ministers, I am ad-vocating that the World Health Assembly adopt a resolution on the topic of sepsis in the coming year. Thanks to all of these measures, we will be helping to decrease the incidence of the disease and reduce sepsis-related mortality rates. This ‚Sepsis Symposium‘ will certainly make a contribution towards achieving that goal.

Hermann GröheFederal MinisterMember of the German Bundestag

7

Foreword

A high mortality and disease burden makes sepsis a feared and devastati ng disease. A speedy diag-nosis and the right treatment are of vital impor-tance for pati ents. And yet, we sti ll know far too litt le about the causes and the impact of sepsis. In additi on to established and practi cable approaches to preventi ng infecti ons, we need eff ecti ve drugs

and treatments to combat sepsis reliably in its early stages.

The Federal Ministry of Educati on and Research has been suppor-ti ng sepsis research for many years. The concept of translati onal research is a driving force in all measures to ensure that people suff ering from sepsis can benefi t as soon as possible from research results. The SepNet competence network, the Centre for Sepsis Control and Care integrated research and treatment centre, the Centre for Innovati on Competence Septomics, the InfectoGnosti cs research campus and the InfectControl2020 project are all lar-ge-scale collaborati ve projects which study both the causes and development of infecti ons and sepsis and its related complicati ons and which aim to develop eff ecti ve therapies.

In spite of its many achievements, research in this fi eld conti nues to be an important topic. The Federal Government will therefore conti nue to parti cipate in nati onal and internati onal initi ati ves and will support research, for example to combat anti bioti c resistance. We also agreed on internati onal acti on in 2015 on the occasion of the German G7 Presidency. However, cooperati on is not only needed across nati onal borders. Cooperati on between individual disciplines is equally important since sepsis is a disease which con-cerns almost all medical disciplines.

I am therefore delighted that the Leopoldina Symposium in Jena is not only providing an opportunity for researchers to conduct exchanges and share the latest research results but has also invited stakeholders in the healthcare sector to fi nd out more, to share in the discussions and to thus provide an important impetus to sepsis research.

Prof. Dr. Johanna WankaFederal Minister of Educati on and Research

Bund

esre

gier

ung/

Steff

en

Kugl

er

8

Integrated Research and Treatment Center

ADVANCINGsepsis treatment and research

INNOVATINGtraining and career prospects

www.cscc.uniklinikum-jena.de

9

ProgramThursday, 10 March 2016

Opening session

Chairs: E. Rietschel, Berlin / P. Suter, Geneva

Start: 10:30

Welcome and introducti onW. Tiefensee, TMWWDG G. Berg, LeopoldinaW. Rosenthal, FSU K. Benndorf, UKJ

10:50 Keynote Lecture:

Role of poverty and environment for public healthA. Steiner, Executi ve Director of United Nati ons Environment Programme (UNEP) and Under-Secretary-General of theUnited Nati ons

11:20

The German strategy for infecti on and sepsis control L. H. Wieler, RKI

11:40

The WHO approach to sepsis controlN. Shindo, WHO

12:00

Lessons to be learned from the Ebola epidemicT. Stöbe, MSF

12:20

The burden of sepsis in childrenN. Kissoon, Canada

12:40

The burden of sepsis - a call to acti onK. Reinhart, Jena

13:00 Lunch Break

10

The challenges of science

Chairs:M. Quintel, Göttingen / T. Hein, Dallas

14:00

Challenges in the development of novel diagnostics and therapeutics in sepsis N. Riedemann, Jena

14:20

Challenges to preserve and develop effective antimicrobialsM. Pletz, Jena

14:40

Role and challenges of clinical sepsis researchS. Finfer, Australia

15:00

Lessons learned from cancerM. Löffler, Leipzig

15:20

Lessons learned from cardiology C. Schulze, Jena

15:40 Coffee Break

Novel approaches to sepsis control and health promotion

Chairs: C. Spies, Berlin / R. Rossaint, Aachen

16:00

The Surviving Sepsis Campaign approach to guideline implementationH. Gerlach, Berlin

16:20

The National Irish initiative to sepsis controlV. Hamilton, Ireland

16:40

The Scottish National Health Service approach to quality improvementK. Rooney, Scotland

11

Novel approaches to sepsis control and health promotion

Chairs: K. Werdan, Halle / M. Weigand, Heidelberg

17:00

The NRC for Surveillance and Nosocomial infection’s approachP. Gastmeier, Berlin

17:20

New approaches to vaccination and health promotionC. Betsch, Erfurt

17:40

The Center for Sepsis Control and Care’s approachH. Rüddel, Jena

18:00

The perspective of a sepsis victimA. Trumann, Heeslingen

Öffentlicher Abendvortrag

Moderation:M. Bucher, Halle 19:00

Sepsis vermeiden und früh erkennenF. M. Brunkhorst, Jena

12

Program Friday, 11 March 2016

Novel approaches to sepsis control and health promotion

Chairs: B. Böttiger, Cologne / B. Löffler, Jena

08:30

The US approach to quality improvement for sepsis managementM. Levy, USA

08:50

Challenges to fight sepsis - in GreeceE. Giamarellos-Bourboulis, Greece

09:10

Preparedness and the role of ICUs in the fight against pandemicsJ. Marshall, Canada

09:30

The Turkish approach to improve sepsis awareness and sepsis management.N. Unal, Turkey

09:50

The Initiative for Quality in Medicine’s approachA. Meier-Hellmann, Erfurt

10:10

The role of media during health crisesJ. Müller-Jung, FAZ

10:30 Coffee break

Roadmap for development of innovative vaccines, diagnostics and therapeutics I

Chairs: T. Koch, Dresden / L. Gattinoni, Milan

13

11:00

The German Center for Infection ResearchD. Heinz, DZIF

11:20

The German Research Platform for ZoonosesT. Mettenleiter, Greifswald

11:40

The SepNet Critical Care Trials groupJ. Briegel, Munich

12:00

The CapNetz Trials groupT. Welte, Hannover

12:20 Lunch break

Roadmap for development of innovative vaccines, diagnostics and therapeutics II

Chairs: J. Schüttler, Erlangen / B. Löffler, Jena

13:00

The Progress ConsortiumN. Suttorp, Berlin

13:20

The Center for Sepsis Control and CareM. Bauer, Jena

13:40

The InfectControl ConsortiumA. Brakhage, Jena

14:00

The InfectoGnostics Research CampusJ. Popp, Jena

14:20

The Center for Innovation Competence SeptomicsO. Kurzai, Jena

14:40

The Center for Infectious Diseases and Infection ControlM. Pletz, Jena

15:00 Coffee break

14

Role of private public partnership for development of innovative vaccines, diagnostics and therapeutics Lessons learned and expectations of:

Chairs: M. Hecker, Greifswald / H. van Aken, Münster

15:30

A researcher and later entrepreneurE. Ermantraut, Blink GmbH Jena

15:50

An international diagnostics corporateV. Liebenberg, Thermo Fisher Scientific Hennigsdorf/Berlin

16:10

A global medical products manufacturerM. Lugan, B. Braun Melsungen AG

16:30

A biotech companyJ. Struck, AdrenoMed AG Hennigsdorf/Berlin

16:50

A university spin-offN. Riedemann, inflaRx Jena

17:10

Closing remarksM. Bauer, Jena

15

Invited speakers and chairs (in alphabetical order)

Bauer Michael, Prof. Dr.Speaker and Chief-Executive Director, Center for Sepsis Control and Care, Jena University HospitalJena, Germany

Benndorf Klaus, Prof. Dr.Scientific Director, Dean of the Faculty of Medicine Jena University HospitalJena, Germany

Berg Gunnar, Prof. Dr. Dr.Vice-President Leopoldina Halle, Germany

Betsch Cornelia, PD Dr.Social, Organisational and Economic Psychology, University of ErfurtErfurt, Germany

Böttiger Bernd, Prof. Dr.Director of the Department of Anaesthesiology and IntensiveCare Medicine, University Hospital CologneCologne, Germany

Brakhage Axel, Prof. Dr.Director, Leibniz Institute for Natural Product Research and Infection Biology, Hans Knöll Institute; Chairman, InfectControl2020, member of the LeopoldinaJena, Germany

Briegel Josef, Prof. Dr.Speaker, SepNet Clinical Trials Group/ Klinik für Anästhesiologie, LMU MunichMunich, Germany

Brunkhorst Frank M., Prof. Dr.Head, ZKS; Endowed Professorship for Clinical Sepsis Research, Department for Anesthesiology and Intensive Care Medicine, Jena University HospitalJena, Germany

Bucher Michael, Prof. Dr.Director, Department of Anesthesiology and Operative Intensive Care Medicine, University Hospital Halle (Saale)Halle/Saale, Germany

16

Ermantraut EugenCEO Blink GmbH; Past CEO, Alere Technologies GmbHJena, Germany

Finfer Simon, Prof. Dr.Professorial Fellow, George Institute for Global Health, Senior Staff Specialist in Intensive Care; Global Sepsis Alliance Board Member; Royal North Shore Hospital of Sydney and Sydney Adventist HospitalSydney, Australia

Gastmeier Petra, Prof. Dr.Director, German National Reference Center for Surveillance of Nosocomial Infections, Institute for Hygiene and Environmental Medicine, Charité - University MedicineBerlin, Germany

Gattinoni Luciano, Prof. Dr.Chief of the Department of Anesthesia, Resuscitation and Pain Therapy, Policlinico Hospital of Milan,University of Milan, Italy

Gerlach Herwig, Prof. Dr.Director, Clinic for Anesthesiology and Critical Care Medicine, Vivantes - Klinikum Neukoelln; President, German Sepsis SocietyBerlin, Germany

Giamarellos-Bourboulis Evangelos, Associate ProfessorUniversity of Athens, Medical SchoolAthens, Greece

Hamilton Vida, M.D.National Clinical Lead Sepsis, Health Service Executive (HSE)Dublin, Ireland

Hecker Michael, Prof. Dr.Professor emeritus, member of the LeopoldinaGreifswald, Germany

Hein H. A. Tillmann, Prof. Dr.Clinical Professor, Department of Anesthesiology and Pain Management, The University of Texas Southwestern Medical SchoolDallas, Texas, U.S.A.

Heinz Dirk, Prof. Dr.Scientific Director, Helmholtz Center for Infection Research; Vice-Chairman Executive Board, German Center for Infection ResearchBraunschweig, Germany

17

Kissoon Niranjan, Prof. Dr.Associate Head, Division of Critical Care, Department of Pediatrics, University of British Columbia; Vice- President, Medical Affairs, BC Children’s HospitalVancouver, Canada

Koch Thea, Prof. Dr.Director, Clinic for Anesthesiology and Critical Care Medicine, University Hospital Carl Gustav Carus Dresden; President German Society of Anesthesiology and Intensive Medicine DGAIDresden, Germany

Kurzai Oliver, Prof. Dr.Speaker, Center for Innovation Competence Septomics; Leibniz Institute for Natural Product Research and Infection Biology, Hans Knöll InstituteJena, Germany

Levy Mitchell M., M.D. Professor of MedicineChief, Division of Pulmonary, Critical Care and Sleep MedicineAlpert Medical School at Brown UniversityDirector, Medical Intensive Care UnitRhode Island HospitalProvidence, RI USA

Liebenberg Volker, Dr.BRAHMS/ ThermoFisher, Director Global Medical AffairsHennigsdorf, Germany

Löffler Bettina, Prof. Dr.Director, Institute for Medical Microbiology, Jena University HospitalJena, Germany

Löffler Markus, Prof. Dr.Director, Institute for Medical Informatics, Statistics and Epidemiology (IMISE), Leipzig UniversityLeipzig, Germany

Lugan Meinrad, Dr.Board Director, B. Braun Melsungen AGMelsungen, Germany

Marshall John, Prof. Dr.Director of Research, Critical Care Medicine, St. Michael’s Hospital; Chair, International Forum for Acute Care Trialists (InFACT); Past-Chair, International Sepsis Forum (ISF)Toronto, Canada

18

Meier-Hellmann Andreas, Prof. Dr.Anesthesiology, Intensive Care Medicine and Pain Therapy, Helios Clinical CenterErfurt, Germany

Mettenleiter Thomas C., Prof. Dr.Friedrich Loeffler Institute, Federal Research Institute for Animal HealthGreifswald - Insel Riems, Germany

Müller-Jung Joachim, Dr.Frankfurter Allgemeine Zeitung/ Head of Department Natur & WissenschaftHerschbach, Germany

Pletz Mathias, Prof. Dr.Head, Center for Infectious Diseases and Infection Control; Deputy CEO Center for Sepsis Control and Care, Jena University HospitalJena, Germany

Popp Jürgen, Prof. Dr.Scientific Director, Leibniz Institute of Photonic Technology e.V.; Professor for Physical Chemistry, Friedrich Schiller University JenaJena, Germany

Quintel Michael, Prof. Dr.Director, Department of Anesthesiology, Göttingen University Hospital, Germany

Reinhart Konrad, Prof. Dr.Director, Department of Anesthesiology and Intensive Care, Jena University Hospital; Chairman Global Sepsis Alliance; Chairman Sepsis-Stiftung, member of the LeopoldinaJena, Germany

Riedemann Niels C., Prof. Dr.CEO InFlarXJena, Germany

Rietschel Ernst,Prof. Dr. Dr. h.c. mult.Chairman of the Board of Directors, Berlin Institute of Health; Former president of the Leibniz AssociationBerlin, Germany

Rooney Kevin, Prof. Dr.Professor of Care Improvement, University of the West of Scotland, Paisley; National Clinical Advisor on Sepsis to Healthcare Improvement ScotlandPaisley, UK

19

Rosenthal Walter, Prof. Dr.President of the Friedrich Schiller University JenaJena, Germany

Rossaint Rolf, Prof. Dr.Director, Department for Anesthesiology, University Hospital AachenAachen, Germany

Rüddel Hendrik, Dr.Department of Anesthesiology and Intensive Care, Jena University HospitalJena, Germany

Schulze P. Christian, MD, PhDDirector, Division of Cardiology, Angiology, Intensive Medical Care and PneumologyJena University HospitalJena, Germany

Schüttler Jürgen, Prof. Dr. med. Dr. h.c.Director, Department of AnesthesiologyErlangen University Hospital, Germany

Shindo Nikki, Prof. Dr.World Health Organization, Department of Pandemic and Epidemic DiseasesGeneva, Switzerland

Spies Claudia, Prof. Dr. Director, Department of Anesthesiology and Operative Intensive Care Medicine, Charité, BerlinBerlin, Germany

Steiner AchimUNEP Executive Director and Under-Secretary-General of the United NationsNairobi, Kenya

Stöbe Tankred, Dr.Chairman; Board of Médecins Sans Frontières GermanyBerlin, Germany

Struck Joachim, Dr.Chief Research Officer, AdrenoMed AGHennigsdorf, Germany

Suter Peter M, Prof. Dr.President, Swiss Medical Board; Former President, Swiss Academy of Medical Sciences, National Ethics CommitteeGeneva, Switzerland

20

Suttorp Norbert, Prof. Dr.Director, Clinic for Infectious Diseases and Pneumology, Charité, BerlinBerlin, Germany

Tiefensee WolfgangThuringian Minister for Economic Affairs, Science and Digital SocietyErfurt, Germany

Trumann ArneSepsis survivorHeeslingen, Germany

Unal Necmettin, Prof. Dr.Anesthesiology and Intensive Care Department of Ankara Medical SchoolAnkara, Turkey

Van Aken Hugo, Prof. Dr. Dr. Director, Department of Anesthesiology, Intensive Care Medicine and Pain TherapyMuenster University Hospital, Germany

Weigand Markus, Prof. Dr.Medical Director, Department for Anesthesiology, Heidelberg University HospitalHeidelberg, Germany

Welte Tobias, Prof. Dr.Chairman, CapNetz Foundation; Head, Department of Respiratory Medicine, Hannover Medical SchoolHannover, Germany

Werdan Karl, Prof. Dr.Professor Emeritus and former Director; Department for Internal Medicine III, University Hospital Halle/SaaleHalle/Saale, Germany

Wieler Lothar-Heinz, Prof. Dr.President, Robert Koch InstituteBerlin, Germany

21

NEW ANTI-INFECTIVE STRATEGIESScience • Society • Economy

InfectControl 2020 - an innovative trans-sectoral consortium developing and commercially implementing novel strategies for successfully fi ghting infectious diseases

22

Scientific organizers

Prof. Dr. Michael BauerCenter for Sepsis Control and Care Jena University Hospital

Prof. Dr. Axel Brakhage, MLInfectControl2020Leibniz Insti tute for Natural Product Research and Infecti on Biology, Hans Knöll Insti tute

Prof. Dr. Konrad Reinhart, ML (Coordinator)Department of Anesthesiology and Intensive Care MedicineJena University Hospital

Registration

www.cscc.uniklinikum-jena.de/leopoldina_symposium.html

23

Supporters

Be sepsis aware.

SupportWorld Sepsis Day,

13 September

Sign the World Sepsis Declaration:

world-sepsis-day.org

lindgruen-gmbh.com

Sepsis affects more than 30 million people worldwide a year. Many of whom die or suffer permanent disabilities.Be sepsis aware and save a life.